Inquiry Basket
Loading ......
Filter By Product Search for
SNV Nucleocapsid
SNV Nucleocapsid Full Name
Sin Nombre Virus Nucleocapsid
SNV Nucleocapsid Introduction
Sin Nombre virus (SNV) nucleocapsid protein (NP) is a 428-amino acid (approximately 48 kDa) structural protein encoded by the S segment of SNV, the most important New World hantavirus responsible for hantavirus pulmonary syndrome (HPS) in North America. SNV was first identified in 1993 during the Four Corners outbreak in the southwestern United States and is maintained in nature by the deer mouse (Peromyscus maniculatus). The NP adopts the conserved three-domain hantavirus nucleoprotein architecture: an N-terminal RNA-binding core domain with a basic cleft for genomic RNA engagement, a central helical oligomerization domain mediating NP-NP trimerization, and a C-terminal domain facilitating higher-order ribonucleoprotein assembly. SNV NP shares approximately 80–85% amino acid identity with other New World hantavirus NPs (e.g., ANDV, NY-1V) and approximately 60% identity with Old World hantavirus NPs. The protein is the most abundant viral antigen expressed during infection and constitutes the major target of both humoral and cellular immune responses.
Figure 1. Sin Nombre Virus as Unlikely Reverse Zoonotic Threat.
SNV NP is central to the viral replication cycle, performing essential roles in RNA encapsidation, ribonucleoprotein assembly, polymerase recruitment, and regulation of the transcription-replication switch. NP binds the 3' and 5' terminal complementary sequences of each viral genome segment, initiating cooperative oligomerization that yields flexible helical ribonucleocapsid filaments. These filaments interact with the viral RdRp and serve as functional templates for both mRNA transcription and genome replication. A critical function of SNV NP is its ability to suppress the host innate antiviral response; the protein sequesters dsRNA from RIG-I and MDA5 sensors, inhibits TRAF3 ubiquitination, blocks TBK1 and IKKε activation, and prevents IRF3 nuclear translocation, collectively blunting type I interferon production. NP also modulates cellular apoptosis pathways through interactions with Fas-mediated signaling. Immunologically, SNV NP is the dominant antigen during acute infection, eliciting early and robust IgM and IgG antibody responses. Multiple CD8+ T cell epitopes restricted by common HLA alleles have been mapped across SNV NP, particularly in the N-terminal and central domains, and are associated with viral clearance in convalescent HPS patients.
SNV NP is the primary diagnostic antigen for HPS in North America, forming the basis of commercially available IgM capture and IgG ELISA assays used by the CDC and public health laboratories. Anti-SNV NP IgM antibodies are typically detectable within 3–7 days of symptom onset, enabling rapid serological confirmation of suspected HPS cases. Recombinant SNV NP expressed in E. coli and eukaryotic systems provides the antigen for these assays and for immunohistochemical detection of viral antigen in tissue specimens. In vaccine development, SNV NP has been included as a component of DNA vaccine candidates, adenovirus-vectored vaccines, and recombinant VLP formulations designed to elicit T cell-mediated immunity. Although NP-based vaccines alone do not induce neutralizing antibodies, they provide important CD8+ T cell contributions to protection when combined with glycoprotein antigens. The NP-RNA binding interface and NP oligomerization surface have been explored as targets for structure-based antiviral drug design, with several candidate compounds showing activity in cell-based assays. SNV NP also serves as a key reagent in ecological surveillance studies monitoring SNV prevalence in deer mouse populations across North America.
Alternate Names for SNV Nucleocapsid
SNV nucleocapsid; SNVsSgp1;
Loading ......
